Satricabtagene autoleucel is under clinical development by CARsgen Therapeutics and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Satricabtagene autoleucel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Satricabtagene autoleucel overview

Satricabtagene autoleucel (CT-041) is under development for the treatment of esophagogastric junction cancer, relapsed or refractory gastric cancer, pancreatic cancer, adenocarcinoma of the stomach and gastroesophageal junction carcinomas. It is administered through intravenous route. The drug candidate is autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human claudin 18.2 antigen with CD28 and CD3-zeta intracellular signaling domains. The drug candidate is being developed based on chimeric antigen receptor (CAR) T cell technology.
It was under development for treatment of colon cancer.

CARsgen Therapeutics overview

CARsgen Therapeutics (CARsgen) operates as a clinical-stage immune-oncology company focuses on developing Chimeric Antigen Receptor T cell therapies for cancer. Its pipeline product includes CAR-GPC3-T for the treatment of late-stage hepatocellular carcinoma (HCC) and lung squamous cell carcinoma; CAR-EGFR targeting Glioblastoma (GBM); CAR-CD19-T against lymphoma and B cell leukemia; CAR-Claudin18.2-T for gastric and pancreatic cancers; and CAR-BCMA-T against multiple myeloma. The company works in strategic partnerships with Shanghai Cancer Institute, Renji Hospital and Changhai Hospital. CARsgen is headquartered in Shanghai, China.

For a complete picture of Satricabtagene autoleucel’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.